0001209191-19-014296.txt : 20190227
0001209191-19-014296.hdr.sgml : 20190227
20190227201746
ACCESSION NUMBER: 0001209191-19-014296
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190225
FILED AS OF DATE: 20190227
DATE AS OF CHANGE: 20190227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Macrae Sandy
CENTRAL INDEX KEY: 0001675687
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 19639965
MAIL ADDRESS:
STREET 1: 721 ST. GEORGES ROAD
CITY: PHILADELPHIA
STATE: PA
ZIP: 19119
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-25
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001675687
Macrae Sandy
C/O SANGAMO THERAPEAUTICS, INC.
POINT RICHMOND TECH CTR, 501 CANAL BLVD.
RICHMOND
CA
94804
1
1
0
0
President and CEO
Common Stock
2019-02-25
4
A
0
63250
0.00
A
90776
D
Stock Option (Right-to-Buy)
9.03
2019-02-25
4
A
0
379500
0.00
A
2029-02-24
Common Stock
379500
379500
D
Represents 63,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Additionally, this amount includes 21,000 shares subject to restricted stock units granted on January 24, 2018 that will vest in two (2) remaining equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.
One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2019 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
/s/ Denise Winn, Attorney-in-Fact for Sandy Macrae
2019-02-27